Pierre Fabre and its Partner Array BioPharma announce the Interim Results of the BEACON CRC Study with Encorafenib plus Binimetinib plus Cetuximab for the Treatment of BRAFV600E-mutant metastatic Colon Cancer (mCRC)

被引：0
|
作者：
不详
机构：
来源：
VISCERAL MEDICINE | 2019年 / 35卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：330 / 330
页数：1
相关论文
共 50 条
  • [1] Updated results of the BEACON CRC safety lead-in: Encorafenib (ENCO) plus binimetinib (BIM) plus cetuximab (CETUX) for BRAFV600E-mutant metastatic colorectal cancer (mCRC).
    Kopetz, Scott
    Grothey, Axel
    Yaeger, Rona
    Cuyle, Pieter-Jan A. R.
    Huijberts, Sanne
    Schellens, Jan H. M.
    Elez, Elena
    Fakih, Marwan
    Viladot, Clara Montagut
    Peeters, Marc
    Desai, Jayesh
    Yoshino, Takayuki
    Ciardiello, Fortunato
    Wasan, Harpreet Singh
    Maharry, Kati
    Christy-Bittel, Janna
    Gollerkeri, Ashwin
    Van Cutsem, Eric
    Tabernero, Josep
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [2] Adverse Events Associated with Encorafenib Plus Cetuximab in Patients with BRAFV600E-mutant Metastatic Colorectal Cancer: An in-depth Analysis of the BEACON CRC Study
    Taieb, Julien
    Lonardi, Sara
    Desai, Jayesh
    Folprecht, Gunnar
    Gallois, Claire
    Marques, Eduardo Polo
    Khan, Sadya
    Castagne, Claire
    Wasan, Harpreet
    [J]. CLINICAL COLORECTAL CANCER, 2023, 22 (01) : 59 - 66
  • [3] ANCHOR CRC: Results From a Single-Arm , Phase II Study of Encorafenib Plus Binimetinib and Cetuximab in Previously Untreated BRAFV600E-Mutant Metastatic Colorectal Cancer
    Van Cutsem, Eric
    Taieb, Julien
    Yaeger, Rona
    Yoshino, Takayuki
    Grothey, Axel
    Maiello, Evaristo
    Elez, Elena
    Dekervel, Jeroen
    Ross, Paul
    Ruiz-Casado, Ana
    Graham, Janet
    Kato, Takeshi
    Ruffinelli, Jose C.
    Andre, Thierry
    Roussel, Edith Carriere
    Klauck, Isabelle
    Groc, Melanie
    Vedovato, Jean-Claude
    Tabernero, Josep
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (14) : 2628 - +
  • [4] BAYONET trial: A multicenter phase II trial of staged combination with encorafenib plus binimetinib plus cetuximab following encorafenib plus cetuximab in patients with BRAFV600E-mutant metastatic colorectal cancer.
    Matsubara, Yuki
    Bando, Hideaki
    Kotani, Daisuke
    Kagawa, Yoshinori
    Harada, Kazuaki
    Osumi, Hiroki
    Izawa, Naoki
    Kawakami, Takeshi
    Boku, Shogen
    Matsumoto, Toshihiko
    Wakabayashi, Masashi
    Yoshino, Takayuki
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : TPS271 - TPS271
  • [5] Effect of prior bevacizumab treatment in BRAF V600E-mutant metastatic colorectal cancer: Overall survival with encorafenib plus cetuximab plus /- binimetinib in BEACON CRC
    Aderka, D.
    Kopetz, S.
    Grothey, A.
    Van Cutsem, E.
    Yaeger, R.
    Wasan, H.
    Yoshino, T.
    Desai, J.
    Ciardiello, F.
    Golden, A.
    Edwards, M.
    Tabernero, J.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S214 - S214
  • [6] Encorafenib plus cetuximab with or without binimetinib for BRAFV600E metastatic colorectal cancer (mCRC): Relationship between carcinoembryonic antigen (CEA) and clinical outcomes from BEACON CRC
    Grothey, A.
    Kopetz, S.
    Yaeger, R.
    Van Cutsem, E.
    Wasan, H.
    Desai, J.
    Ciardiello, F.
    Yoshino, T.
    Maharry, K.
    Christy-Bittel, J.
    Gollerkeri, A.
    Tabernero, J.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 : S243 - S243
  • [7] Safety and Efficacy of Encorafenib, Binimetinib, and Cetuximab for BRAFV600E-Mutant Metastatic Colorectal Cancer: Results of the Japanese Expanded Access Program
    Kotani, Daisuke
    Takashima, Atsuo
    Kato, Takeshi
    Satoh, Taroh
    Masuishi, Toshiki
    Komatsu, Yoshito
    Shiozawa, Manabu
    Esaki, Taito
    Izawa, Naoki
    Takeuchi, Shinji
    Bando, Hideaki
    Iwasa, Satoru
    Hasegawa, Hiroko
    Yamaguchi, Toshifumi
    Taniguchi, Hiroya
    Ushida, Yasunori
    Oizaki, Toshiya
    Inoue, Chiaki
    Yoshino, Takayuki
    [J]. CLINICAL COLORECTAL CANCER, 2024, 23 (02)
  • [8] BREAKWATER: Randomized phase 3 study of encorafenib (enco) plus cetuximab (cet) ± chemotherapy for first-line treatment (tx) of BRAFV600E-mutant (BRAFV600) metastatic colorectal cancer (mCRC)
    Kopetz, Scott
    Grothey, Axel
    Yaeger, Rona
    Ciardiello, Fortunato
    Desai, Jayesh
    Kim, Tae Won
    Maughan, Tim
    Van Cutsem, Eric
    Wasan, Harpreet Singh
    Yoshino, Takayuki
    Edwards, Michelle L.
    Golden, Adele
    Gollerkeri, Ashwin
    Tabernero, Josep
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [9] SEAMARK: phase II study of first-line encorafenib and cetuximab plus pembrolizumab for MSI-H/dMMR BRAFV600E-mutant mCRC
    Elez, Elena
    Kopetz, Scott
    Tabernero, Josep
    Bekaii-Saab, Tanios
    Taieb, Julien
    Yoshino, Takayuki
    Manji, Gulam
    Fernandez, Kathrine
    Abbattista, Antonello
    Zhang, Xiaosong
    Morris, Van K.
    [J]. FUTURE ONCOLOGY, 2024, 20 (11) : 653 - 663
  • [10] Quality of life with encorafenib plus cetuximab with or without binimetinib treatment in patients with BRAF V600E-mutant metastatic colorectal cancer: patient-reported outcomes from BEACON CRC
    Kopetz, S.
    Grothey, A.
    Van Cutsem, E.
    Yaeger, R.
    Wasan, H.
    Yoshino, T.
    Desai, J.
    Ciardiello, F.
    Loupakis, F.
    Hong, Y. S.
    Steeghs, N.
    Guren, T. K.
    Arkenau, H-T
    Garcia-Alfonso, P.
    Belani, A.
    Zhang, X.
    Tabernero, J.
    [J]. ESMO OPEN, 2022, 7 (03)
12345